A comparison between the continual reassessment method andD-optimum design for dose finding in phase I clinical trials
Biometrical Letters (2016)
- Volume: 53, Issue: 2, page 69-82
- ISSN: 1896-3811
Access Full Article
topAbstract
topHow to cite
topM. Iftakhar Alam. "A comparison between the continual reassessment method andD-optimum design for dose finding in phase I clinical trials." Biometrical Letters 53.2 (2016): 69-82. <http://eudml.org/doc/287112>.
@article{M2016,
abstract = {The continual reassessment method is a model-based procedure, described in the literature, used to determine the maximum tolerated dose in phase I clinical trials. The maximum tolerated dose can also be found under the framework of D-optimum design, where information is gathered in such a way so that asymptotic variability in the parameter estimates in minimised. This paper investigates the two methods under some realistic settings to explore any potential differences between them. Simulation studies for six plausible dose-response scenarios show that D-optimum design can work well in comparison with the continual reassessment method in many cases. The D-optimum design is also found to allocate doses from the extremes of the design region to the patients in a trial.},
author = {M. Iftakhar Alam},
journal = {Biometrical Letters},
keywords = {Dose finding studies; Phase I trial; Maximum tolerated dose; Continual reassessment method; D-optimum design},
language = {eng},
number = {2},
pages = {69-82},
title = {A comparison between the continual reassessment method andD-optimum design for dose finding in phase I clinical trials},
url = {http://eudml.org/doc/287112},
volume = {53},
year = {2016},
}
TY - JOUR
AU - M. Iftakhar Alam
TI - A comparison between the continual reassessment method andD-optimum design for dose finding in phase I clinical trials
JO - Biometrical Letters
PY - 2016
VL - 53
IS - 2
SP - 69
EP - 82
AB - The continual reassessment method is a model-based procedure, described in the literature, used to determine the maximum tolerated dose in phase I clinical trials. The maximum tolerated dose can also be found under the framework of D-optimum design, where information is gathered in such a way so that asymptotic variability in the parameter estimates in minimised. This paper investigates the two methods under some realistic settings to explore any potential differences between them. Simulation studies for six plausible dose-response scenarios show that D-optimum design can work well in comparison with the continual reassessment method in many cases. The D-optimum design is also found to allocate doses from the extremes of the design region to the patients in a trial.
LA - eng
KW - Dose finding studies; Phase I trial; Maximum tolerated dose; Continual reassessment method; D-optimum design
UR - http://eudml.org/doc/287112
ER -
NotesEmbed ?
topTo embed these notes on your page include the following JavaScript code on your page where you want the notes to appear.